| Type 2 Diabetes Mellitus |
1 |
1 |
| SGLT2 Inhibitor |
0 |
0.76 |
| GLP-1 Receptor Agonist |
0 |
0.43 |
| Drug Costs |
0 |
0.25 |
| Generics |
0 |
0.25 |
| Health Care Inequities |
0 |
0.25 |
| Receptors |
0 |
0.25 |
| Clinical Guidelines |
0 |
0.23 |
| Congestive Heart Failure |
0 |
0.18 |
| Coronary Artery Disease (CAD) |
0 |
0.18 |
| Heart |
0 |
0.17 |
| Cerebrovascular Accident |
0 |
0.08 |
| Chronic Disease |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Grant |
0 |
0.08 |
| Hand |
0 |
0.08 |
| Healthcare and Medical Technology |
0 |
0.08 |
| Infarction |
0 |
0.08 |
| Insurance |
0 |
0.08 |
| Kidney |
0 |
0.08 |
| Myocardial Infarction (MI) |
0 |
0.08 |
| Nutrition |
0 |
0.08 |
| Quality of Life |
0 |
0.08 |
| Revenue and Practice Management |
0 |
0.08 |
| UK Site Content |
0 |
0.08 |